Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...
PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...
New Insulin in Prefilled Pen Gets FDA Nod Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve ...
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve ...
Sanofi has been boosted by the news that the US Food and Drug Administration has approved Toujeo, the follow-up to its diabetes blockbuster Lantus. Sanofi has been boosted by the news that the US Food ...
Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients in type I diabetes. Sanofi has unveiled real-world data from ...
The FDA approves Sanofi's (NASDAQ:SNY) Toujeo (insulin glargine 300 Units/mL) Max SoloStar. The product holds 900 Units of Toujeo and can deliver up to 160 Units in a single injection. The company ...
The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...
Paris, France - February 27, 2015 - Sanofi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion ...
Sanofi’s experimental insulin Toujeo controlled diabetes better than the company’s best-selling Lantus in three tests that suggest the new drug may help buoy sales when the older one loses patent ...